Marc DePaul
Director of Research & NVG-291 Project Leader at NervGen Pharma Corp. - Vancouver, BC, US
Marc DePaul's Colleagues at NervGen Pharma Corp.
Marc DePaul's Contact Details
V7X 1J1
NervGen Pharma Corp.
Marc DePaul's Company Details
NervGen is a publicly traded (TSX-V: NGEN, OTCQX: NGENF) clinical stage biotech company dedicated to discovering and developing innovative treatments for nervous system damage, due to injury or disease. NervGen's lead drug candidate, NVG-291, is a first of its kind experimental drug administered by injection under the skin.NVG-291 relieves the inhibitory effects of CSPGs and thus enables nervous system repair. In animal studies, this therapeutic approach promoted nervous system repair and enhanced recovery of functions such as walking, bladder control, vision, and memory.NVG-291 entered Phase 1 clinical trials in 2021. After completing our Phase 1 clinical trial, we plan to study the effectiveness and safety of NVG-291 initially in people with spinal cord injury, Alzheimer's disease and multiple sclerosis.